Cargando…
Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009
BACKGROUND: Post-molar pregnancy gestational trophoblastic tumours (GTT) have been curable with chemotherapy treatment for over 50 years. Because of the rarity of the diagnosis, detailed structured information on prognosis, treatment escalations and outcome is limited. METHODS: We have reviewed the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504950/ https://www.ncbi.nlm.nih.gov/pubmed/23059744 http://dx.doi.org/10.1038/bjc.2012.462 |
_version_ | 1782250709096333312 |
---|---|
author | Sita-Lumsden, A Short, D Lindsay, I Sebire, N J Adjogatse, D Seckl, M J Savage, P M |
author_facet | Sita-Lumsden, A Short, D Lindsay, I Sebire, N J Adjogatse, D Seckl, M J Savage, P M |
author_sort | Sita-Lumsden, A |
collection | PubMed |
description | BACKGROUND: Post-molar pregnancy gestational trophoblastic tumours (GTT) have been curable with chemotherapy treatment for over 50 years. Because of the rarity of the diagnosis, detailed structured information on prognosis, treatment escalations and outcome is limited. METHODS: We have reviewed the demographics, prognostic variables, treatment course and clinical outcomes for the post-mole GTT patients treated at Charing Cross Hospital between 2000 and 2009. RESULTS: Of the 618 women studied, 547 had a diagnosis of complete mole, 13 complete mole with a twin conception and 58 partial moles. At the commencement of treatment, 94% of patients were in the FIGO low-risk group (score 0–6). For patients treated with single-agent methotrexate, the primary cure rate ranged from 75% for a FIGO score of 0–1 through to 31% for those with a FIGO score of 6. CONCLUSION: In the setting of a formal follow-up programme, the expected cure rate for GTT after a molar pregnancy should be 100%. Prompt treatment and diagnosis should limit the exposure of most patients to combination chemotherapy. Because of the post-treatment relapse rate of 3% post-chemotherapy, hCG monitoring should be performed routinely. |
format | Online Article Text |
id | pubmed-3504950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-35049502013-11-20 Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 Sita-Lumsden, A Short, D Lindsay, I Sebire, N J Adjogatse, D Seckl, M J Savage, P M Br J Cancer Clinical Study BACKGROUND: Post-molar pregnancy gestational trophoblastic tumours (GTT) have been curable with chemotherapy treatment for over 50 years. Because of the rarity of the diagnosis, detailed structured information on prognosis, treatment escalations and outcome is limited. METHODS: We have reviewed the demographics, prognostic variables, treatment course and clinical outcomes for the post-mole GTT patients treated at Charing Cross Hospital between 2000 and 2009. RESULTS: Of the 618 women studied, 547 had a diagnosis of complete mole, 13 complete mole with a twin conception and 58 partial moles. At the commencement of treatment, 94% of patients were in the FIGO low-risk group (score 0–6). For patients treated with single-agent methotrexate, the primary cure rate ranged from 75% for a FIGO score of 0–1 through to 31% for those with a FIGO score of 6. CONCLUSION: In the setting of a formal follow-up programme, the expected cure rate for GTT after a molar pregnancy should be 100%. Prompt treatment and diagnosis should limit the exposure of most patients to combination chemotherapy. Because of the post-treatment relapse rate of 3% post-chemotherapy, hCG monitoring should be performed routinely. Nature Publishing Group 2012-11-20 2012-10-11 /pmc/articles/PMC3504950/ /pubmed/23059744 http://dx.doi.org/10.1038/bjc.2012.462 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Sita-Lumsden, A Short, D Lindsay, I Sebire, N J Adjogatse, D Seckl, M J Savage, P M Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title | Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title_full | Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title_fullStr | Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title_full_unstemmed | Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title_short | Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 |
title_sort | treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the charing cross hospital, 2000–2009 |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504950/ https://www.ncbi.nlm.nih.gov/pubmed/23059744 http://dx.doi.org/10.1038/bjc.2012.462 |
work_keys_str_mv | AT sitalumsdena treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT shortd treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT lindsayi treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT sebirenj treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT adjogatsed treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT secklmj treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 AT savagepm treatmentoutcomesfor618womenwithgestationaltrophoblastictumoursfollowingamolarpregnancyatthecharingcrosshospital20002009 |